Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

Cuartero-Martínez, Andrea; García-Otero, Xurxo; Codesido, Jessica; Gómez-Lado, Noemí; Mateos, Jesús; Bravo, Susana B.; Rodríguez-Fernández, Carmen Antía; González-Barcia, Miguel; Aguiar, Pablo; Ortega-Hortas, Marcos; Otero-Espinar, Francisco J.; Fernández-Ferreiro, Anxo

doi:10.1016/j.ijpharm.2024.124516

International Journal of Pharmaceutics

2024

DOI: 10.1016/j.ijpharm.2024.124516

|View full text |Cite

Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

Andrea Cuartero-Martínez,

Xurxo García-Otero,

Jessica Codesido

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Monoclonal Antibodies for the Treatment of Ocular Diseases

Henriques,

da Ana,

Krambeck

et al. 2024

JCM

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) have revolutionized the landscape of cancer therapy, offering unprecedented specificity and diverse mechanisms to combat malignant cells. These biologic agents have emerged as a cornerstone in targeted cancer treatment, binding to specific antigens on cancer cells and exerting their therapeutic effects through various mechanisms, including inhibition of signaling pathways, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). The unique ability of mAbs to engage the immune system and directly interfere with cancer cell function has significantly enhanced the therapeutic armamentarium against a broad spectrum of malignancies. mAbs were initially studied in oncology; however, today, treatments have been developed for eye diseases. This review discusses the current applications of mAbs for the treatment of ocular diseases, discussing the specificity and the variety of mechanisms by which these molecules exhibit their therapeutic effects. The benefits, drawbacks, effectiveness, and risks associated with using mAbs in ophthalmology are highlighted, focusing on the most relevant ocular diseases and mAbs currently in use. Technological advances have led to in vitro production methods and recombinant engineering techniques, allowing the development of chimeric, humanized, and fully human mAbs. Nowadays, many humanized mAbs have several applications, e.g., for the treatment of age-related macular disease, diabetic retinopathy, and uveitis, while studies about new applications of mAbs, such as for SARS-CoV-2 infection, are also currently ongoing to seek more efficient and safe approaches to treat this new ocular disease.

show abstract

Monoclonal Antibodies for the Treatment of Ocular Diseases

Henriques,

da Ana,

Krambeck

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Preclinical characterization of endotoxin-induced uveitis models using OCT, PET/CT and proteomics

Cited by 1 publication

References 66 publications

Monoclonal Antibodies for the Treatment of Ocular Diseases

Monoclonal Antibodies for the Treatment of Ocular Diseases

Contact Info

Product

Resources

About